Objectives: To compare the overall birth prevalence of diagnosed glycogen storage disease type II (GSD II) with the predicted frequency based on mutation screening, in order to determine whether GSD II is an underdiagnosed condition, and to analyze which medical disciplines recognize GSD II. Methods: Retrospective data on all enzymatic diagnoses of GSD II were collected from diagnostic labs throughout the Netherlands, covering the period from January 1, 1972 to December 31, 1996. Age-specific diagnostic incidence rates were calculated for the entire study period. By adding together the diagnostic incidences for all age groups, we calculated the birth prevalence of diagnosed GSD II and compared these figures with the predicted frequency based on mutation screening in a random sample from the general population. The medical specialization of the referring clinicians was also recorded. Results: GSD II was diagnosed in 154 individuals, including 11 prenatal diagnoses. The birth prevalences of the various phenotypes were 1/101,000 (infantile form), 1/720,000 (juvenile form) and 1/53,000 (adult form). The birth prevalence of the adult and infantile phenotype together was 1/35,000. Eighty-two percent of the patients were diagnosed in university hospitals. Of the patients with infantile GSD II, 71% were diagnosed by a pediatrician, whereas most patients with adult GSD II were diagnosed by a neurologist (80%). Conclusions: There is no evidence for the underdiagnosis of GSD II in the Netherlands, as the calculated birth prevalences of the disease are consistent with previous predictions based on mutation screening in a random sample of newborns. The worldwide birth prevalence of the disease may well be higher than 1 in 100,000. GSD II is mainly diagnosed in university hospitals.

Keywords:
Pompe’s disease, Birth prevalence, Glycogenosis
1.
Hirschhorn R: Glycogen storage disease type II: Acid α-glucosidase (acid maltase) deficiency; in Scriver CR, Beaudet AL, Sly W, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 1994, pp 2443–2464.
2.
Wokke JHJ, Ausems MGEM, Van den Boogaard MJH, Ippel PF, Van Diggelen OP, Kroos MA, Boer M, Jennekens FGI, Reuser AJJ, Ploos van Amstel HK: Genotype-phenotype correlation in adult-onset acid maltase deficiency. Ann Neurol 1995;38:450–454.
3.
Reuser AJJ, Kroos MA, Hermans MMP, Bijvoet AGA, Verbeet MP, Van Diggelen OP, Kleijer WJ, Van der Ploeg AT: Glycogenosis type II (acid maltase deficiency). Muscle Nerve 1995;3:S61–69.
4.
Sidbury JB: The genetics of the glycogen storage diseases; in Steinberg AG, Bearn AG, (eds): Progress in Medical Genetics. New York, Grune & Stratton, 1967, pp 32–58.
5.
Schaub J, Bayerl P: Incidence of glycogen storage disease in the German Federal Republic. Z Kinderheilkd 1975;120:79–85.
6.
Loonen MCB: The variability of Pompe’s disease. A clinical, biochemical and genetic study of glycogen storage disease type II; academic thesis; Erasmus University, Rotterdam, 1979.
7.
Meikle PJ, Hopwood JJ, Clague AE, Carey WF: Prevalence of lysosomal storage disorders. JAMA 1999;281:249–254.
8.
Ausems MGEM, Verbiest J, Hermans MMP, Kroos MA, Beemer FA, Wokke JHJ, Sandkuijl LA, Reuser AJJ, Van der Ploeg AT: The frequency of glycogen storage disease type II in the Netherlands: Implications for diagnosis and genetic counseling. Eur J Hum Genet 1999;7:713–716.
9.
Martiniuk F, Chen A, Mack A, Arvanitopoulos E, Chen Y, Rom WN, Codd WJ, Hanna B, Alcabes PH, Raben N, Plotz R: Carrier frequency for glycogen storage disease type II in New York and estimates of affected individuals born with the disease. Am J Med Genet 1998;79:69–72.
10.
Ausems MGEM, Lochman P, Van Diggelen OP, Ploos van Amstel HK, Reuser AJJ, Wokke JHJ: A diagnostic protocol for adult-onset glycogen storage disease type II. Neurology 1999;52:851–853.
11.
Kleijer WJ, Van der Kraan M, Kroos MA, Groener JEM, Van Diggelen OP, Reuser AJJ, Van der Ploeg AT: Prenatal diagnosis of glycogen storage disease type II: Enzyme assay or mutation analysis? Pediatr Res 1995;38:103–106.
12.
MacMahon B, Trichopoulos D: Cohort studies; in Stranglis JT, Ellis DK (eds): Epidemiology: Principles and Methods. Boston, Little, Brown, 1996, pp 218–222.
13.
Poorthuis BJHM, Wevers RA, Kleijer WJ, Groener JEM, De Jong JGN, Van Weely S, Niezen-Koning KE, Van Diggelen OP: The frequency of lysosomal storage diseases in the Netherlands. Hum Genet 1999;105:151–156.
14.
Chen YT, Burcell A: Glycogen storage diseases; in Scriver CR, Beaudet AL, Sly W, Valle D (eds): The Metabolic and Molecular Bases of Inherited Disease. New York, McGraw-Hill, 1994, pp 935–965.
15.
Kroos MA, Van der Kraan M, Van Diggelen OP, Kleijer WJ, Reuser AJJ, Van den Boogaard MJ, Ausems MGEM, Ploos van Amstel HK, Poenaru L, Nicolino M, Wevers R: Glycogen storage disease type II: Frequency of three common mutant alleles and their associated clinical phenotypes studied in 121 patients. J Med Genet 1995;32:836–837.
16.
Huie ML, Chen AS, Tsujino S, Shanske S, DiMauro S, Engel AG, Hirschhorn R: Aberrant splicing in adult onset glycogen storage disease type II (GSDII): Molecular identification of an IVS1 (–13T→G) mutation in a majority of patients and a novel IVS10 (+1GT→CT) mutation. Hum Mol Genet 1994;3:2231–2236.
17.
Hirschhorn R, Huie ML: Frequency of mutations for glycogen storage disease type II in different populations: The Δ525T and Δexon 18 mutations are not generally ‘common’ in white populations. J Med Genet 1999;36:85–86.
18.
Keunen RWM, Lambregts PCLA, Op de Coul AAW, Joosten EMG: Respiratory failure as initial symptom of acid maltase deficiency. J Neurol Neurosurg Psychiatry 1984;47:549–552.
19.
Bijvoet AGA, Kroos MA, Pieper FR, Van der Vliet M, De Boer HA, Van der Ploeg AT, Verbeet MPh, Reuser AJJ: Recombinant human acid α-glucosidase: High level production in mouse milk, biochemical characteristics, correction of enzyme deficiency in GSDII KO mice. Hum Mol Genet 1998;7:1815–1824.
20.
Kikuchi T, Yang HW, Pennybacker M, Ichihara N, Mizutani M, Van Hove JLK, Chen YT: Clinical and metabolic correction of Pompe disease by enzyme therapy in acid maltase-deficient quail. J Clin Invest 1998;101:827–833.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.